Track Advaxis's EBIT ($-36M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2023
Trailing 12 months ending Dec 31, 2023
As of the most recent data (December 2023), ADXS shows a EBIT of $-36M. That compares with $-25M in the prior-year period — down 46.1% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ADXS's EBIT is now $-36M (was $-25M) — a 46.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Advaxis is outperforming or lagging.
The Healthcare sector average EBIT is about $1.9T. Advaxis is at $-36M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how ADXS stacks up against individual peers as well.
Tracking ADXS's ebit over time shows whether Advaxis is scaling, shrinking, or reshaping that part of the business. The current reading is $-36M That compares with $-25M in the prior-year period — down 46.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Advaxis's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-36M) with ownership activity and broader fundamentals.